Laurak (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal firing and diminishes the hyper‑excitability that underlies seizure activity, without directly influencing ion channels or GABAergic pathways.

The dosage of Laurak is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Physicians determine the appropriate starting dose and any subsequent titration to achieve optimal seizure control while minimizing side effects.

Levetiracetam’s pregnancy category is listed as unknown, and limited data exist on its safety in pregnant or lactating women. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative options when appropriate.

To request Laurak, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam (Laurak) has a relatively favorable drug‑interaction profile and does not require routine therapeutic drug monitoring. However, individual response varies, and clinicians may choose alternative agents based on seizure type, comorbidities, and tolerability.

Laurak should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

Laurak is taken orally, usually with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, though uncommon, include severe allergic reactions, Stevens‑Johnson syndrome, suicidal thoughts or behaviors, marked depression, and rare blood‑cell abnormalities. Patients should seek immediate medical attention if they experience rash, mood changes, or signs of infection.

Laurak is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking medications that markedly reduce levetiracetam levels without appropriate monitoring.